SurgiLight Acquires Exclusive Worldwide Licensing Rights to a Multi-Wavelength Medical Laser.

Business Editors/Health, Medical & Technology Writers

ORLANDO, Fla.--(BUSINESS WIRE)--Nov. 9, 2000

SurgiLight,Inc., (OTCBB:SRGL), announced that it has acquired the exclusive worldwide licensing rights to a diode-pumped multi-wavelength laser for medial applications patented by Lowell Crow.

Pursuant to the terms of the Licensing Agreement, the Company will own a worldwide, exclusive license (including the right to sub-license), to make, use, export, offer for sale and sell Licensed Products which are covered by US Patent No. 5,243,798 (the "798 Patent"). To acquire the patented technology, the Company agrees to issue 3,100 shares of its common stock to the licensor and pay a 5% royalty fee from the net sale price of the licensed products. This 798 Patent covers the use of a solid state ophthalmic laser apparatus for photocoagulating and photoablating ocular tissue. This patent also covers the use of multi-wavelength semiconductor laser and diode-pumped Er:YAG laser which are coupled to a single optical.

J.T. Lin, Ph.D. President & CEO commented, "The additional intellectual properties, patents and FDA clearances further solidifies our technological advantage over our competitors."

Dr. J.T. Lin has also filed a new US patent on Nov. 3, 2000 for the use of fiber-coupled lasers for the new procedure of "presbyopia correction" which has a potential market of $150 billion in US. The Company currently owns 5 of the 18 pending patents directly related to "Laser Presbyopia Reversal".

The Company believes that this Licensing Right will accelerate the Company's development of future new products of diode-pumped infrared lasers (DPIR) for various medial applications. The DPIR system may replace many of the existing laser systems and offer the advantages of being compact (15 pounds versus 150 pounds) and more reliable (at least 50 times longer lifetime).

After these Licensing Rights, the Company will own 15 patents and an additional 18 pending patents covering a broad range of laser spectra and their medical applications. The Company believes that these intellectual properties secure its leading position in the IR-laser technology for medical applications.

As announced previously, the Company also acquired from Premier Lasers 14 patents which cover the use of infrared Erbium laser for three of the most important areas of ophthalmic applications: glaucoma, cataract and refractive surgery. In addition to Premier's FDA clearances, the Company intends to continue the ongoing clinical trials in cataract treatment and other applications using the Erbium laser.

The Company is aggressively pursuing domestic representatives for these new ophthalmic products and the recently FDA cleared EX-308 laser for psoriasis treatment.

The Company believes that it is the first company to own the technology of "Laser Presbyopia Reversal" with 5 pending patents in U.S.

The Company's new product, model IR-3000, for presbyopia correction is fundamentally different from the thermal IR laser made by Sunrise (Nasdaq:SNRS) and the UV lasers made by VISX (NYSE:EYE), LaserSight (Nasdaq:LASE), Bausch and Lomb (NYSE:BOL) and Nidek (Japan).

SurgiLight is a world leader in the development of ultraviolet lasers and new infrared technologies, a pioneer and inventor of scanning lasers and lasers for presbyopia reversal with four patents submitted in the U.S. The Company continues to receive royalty income from international eye laser and cosmetic centers.

This press release may contain forward-looking statements regarding future events and performance of the Company, which involves risks and uncertainties that could materially affect actual results. Investors should refer to documents that the Company files with the SEC for a description of certain factors that could cause actual results to vary from current expectations and the forward-looking statements contained in this press release.